iCure Pharmaceutical said Thursday that it has presented the phase 1 clinical trial result for its Donepezil patch, the most commonly used treatment for dementia, at the 2018 Alzheimer’s Association International Conference.

The company is a research and development firm, which has an original technology for Transdermal Drug Delivery System (TDDS), and is working on a patch to help patients attach it twice a week.

The trial result showed that the company’s patch had an equivalent effect in blood concentration profile when compared with conventional Donepezil pills consumed once a day. The patch was more stable in controlling the initial blood concentration and the fluctuation of the blood concentration.

According to iCure, in the case of oral formulations, the fluctuation of blood concentration is so severe that it causes side effects of drugs such as gastrointestinal disorder and kidney problem. However, the company’s patch can maintain the blood concentration only in the therapeutic effect range without the side effects.

The company executives will return to Korea next month after completing a business meeting with CRO companies for clinical trials in the U.S. iCure is currently running the world's first multi-national phase 3 clinical trials for Donepezil patch and plans to complete the research by the end of next year.

iCure aims to commercialize the product by 2020 after finishing its phase 3 clinical trials in Korea, Australia, Taiwan, and Malaysia next year.

“As the world's first company, which is running phase 3 clinical trials for Donepezil dementia patch, our product has attracted a great deal of attention from international researchers,” iCure Ceo Choi Young-kweon said.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>